Kharkevich D A, Churukanov V V
Department of Pharmacology, Moscow Medical Academy, Russia.
Eur J Pharmacol. 1999 Jun 30;375(1-3):121-31. doi: 10.1016/s0014-2999(99)00264-2.
Clinical and experimental data indicate that the cerebral cortex plays an important role in pain perception and endogenous antinociceptive system function. Moreover, the enhancement of descending inhibitory cortical control may be involved in the mechanisms of analgetic effect of some agents. The present study was designed to investigate the effect of cortical electrical stimulation (as a model of descending inhibitory control) on the behavioral and electrophysiological signs of nociceptive response, decipher the mechanisms involved therein and evaluate the action of central analgesics (both opioid and non-opioid) on descending cortical control. In acute experiments in cats the inhibitory cortical influence on neuronal activity produced by nociceptive stimuli (electrical stimulation of tooth pulp, C-fibers of afferent somatic nerves, afferent cardiac structures) was most marked after stimulation of the first and second sensory and fronto-orbital areas. In chronic experiments on rats cortical stimulation reduced behavioral signs of visceral pain (writhing test) and also delayed the development of neuropathic pain syndrome along with lowering its intensity. Mu-opioid receptor agonists (morphine, fentanyl) potentiated the inhibitory cortical effect on the evoked neuronal activity. Pentazocine, which has pronounced kappa-receptor agonistic activity, was less effective. Naloxone eliminated the effects of both cortical stimulation and opioid analgesics. Serotonin receptor antagonist methysergide as well as p-chlorophenylalanine significantly decreased inhibitory cortical control and opioids effect. Monoamine re-uptake inhibitors with analgetic properties (imipramine, fluoxetine) potentiated the inhibitory effect of cortical stimulation. Adrenoceptor, dopamine, acetylcholine, GABA-receptor agents and antagonists of NMDA receptors had minor or no effect. Among non-narcotic analgesics, inhibitors of cyclooxygenase, metamysole and ketorolak increased only moderately the descending cortical control of nociception. Thus, the cerebral cortex is able to control the nociceptive processing in different pain syndromes (somatic, visceral or neuropathic pain). Opioidergic and serotonergic systems play the key role in this control. The effect over the cortical descending control is likely to be one of the components of the analgetic effect exerted by opioids and some other central analgesics.
临床和实验数据表明,大脑皮层在疼痛感知和内源性抗痛系统功能中发挥着重要作用。此外,下行抑制性皮层控制的增强可能参与了某些药物镇痛作用的机制。本研究旨在探讨皮层电刺激(作为下行抑制性控制的模型)对伤害性反应的行为和电生理指标的影响,解读其中涉及的机制,并评估中枢镇痛药(阿片类和非阿片类)对皮层下行控制的作用。在猫的急性实验中,在刺激第一和第二感觉区以及额眶区后,皮层对伤害性刺激(牙髓电刺激、传入躯体神经的C纤维、传入心脏结构)所产生的神经元活动的抑制作用最为明显。在大鼠的慢性实验中,皮层刺激减少了内脏疼痛的行为指标(扭体试验),并延缓了神经病理性疼痛综合征的发展,同时降低了其强度。μ-阿片受体激动剂(吗啡、芬太尼)增强了皮层对诱发神经元活动的抑制作用。具有明显κ-受体激动活性的喷他佐辛效果较差。纳洛酮消除了皮层刺激和阿片类镇痛药的作用。5-羟色胺受体拮抗剂麦角新碱以及对氯苯丙氨酸显著降低了皮层抑制性控制和阿片类药物的作用。具有镇痛特性的单胺再摄取抑制剂(丙咪嗪、氟西汀)增强了皮层刺激的抑制作用。肾上腺素能受体、多巴胺、乙酰胆碱、GABA受体药物以及NMDA受体拮抗剂作用轻微或无作用。在非麻醉性镇痛药中,环氧化酶抑制剂、美他佐辛和酮咯酸仅适度增强了皮层对伤害性感受的下行控制。因此,大脑皮层能够控制不同疼痛综合征(躯体性、内脏性或神经性疼痛)中的伤害性处理过程。阿片能和5-羟色胺能系统在这种控制中起关键作用。对皮层下行控制的影响可能是阿片类药物和其他一些中枢镇痛药镇痛作用的组成部分之一。